A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Phase 4CompletedNCT00445094

Merck Sharp & Dohme LLC120 enrolled

Overview

The primary objective of this study is a comparison between MK0787B and standard therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Infection Pneumonia

Interventions

MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 DaysDRUG

Comparator: amikacin / Duration of Treatment: 3 DaysDRUG

Comparator: tazocin / Duration of Treatment: 3 DaysDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Greater than 18 years of age * Patient is diagnosed with nosocomial pneumonia Exclusion Criteria: * Immunological deficient patients * Pregnant women and nursing mothers * A fungus is identified before the study enrollment * Received vancomycin or imipenem for more than 5 days before icu admission

Outcomes

Primary Outcomes

A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.